Stay updated with breaking news from Nasdaq Carm. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Shares of Carisma Therapeutics, Inc. (NASDAQ:CARM – Get Free Report) rose 0.4% on Tuesday . The stock traded as high as $2.60 and last traded at $2.54. Approximately 233,084 shares changed hands during trading, an increase of 72% from the average daily volume of 135,874 shares. The stock had previously closed at $2.53. Wall Street […]
Carisma Therapeutics, Inc. (NASDAQ:CARM – Get Free Report) has received a consensus recommendation of “Buy” from the five brokerages that are currently covering the stock, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy recommendation. The average 12-month target price among brokerages that have covered the stock in the last year […]
Carisma Therapeutics, Inc. (NASDAQ:CARM – Get Free Report) has been assigned an average recommendation of “Buy” from the five brokerages that are presently covering the stock, Marketbeat Ratings reports. Five research analysts have rated the stock with a buy recommendation. The average 1-year target price among brokerages that have updated their coverage on the stock […]
Carisma Therapeutics, Inc. (NASDAQ:CARM – Get Free Report) saw a large decrease in short interest in September. As of September 15th, there was short interest totalling 2,580,000 shares, a decrease of 8.5% from the August 31st total of 2,820,000 shares. Based on an average trading volume of 234,300 shares, the short-interest ratio is currently 11.0 […]
Carisma Therapeutics (NASDAQ:CARM – Get Free Report)‘s stock had its “buy” rating restated by HC Wainwright in a research note issued on Wednesday, Benzinga reports. They presently have a $11.00 price target on the stock. HC Wainwright’s price objective would suggest a potential upside of 121.33% from the stock’s previous close. Other analysts have also […]